Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Tax Provisions (2022 - 2024)

Historic Tax Provisions for Amylyx Pharmaceuticals (AMLX) over the last 3 years, with Q4 2024 value amounting to -$1.0 million.

  • Amylyx Pharmaceuticals' Tax Provisions fell 15139.66% to -$1.0 million in Q4 2024 from the same period last year, while for Sep 2025 it was -$1.0 million, marking a year-over-year decrease of 14577.11%. This contributed to the annual value of -$770000.0 for FY2024, which is 11466.67% down from last year.
  • Per Amylyx Pharmaceuticals' latest filing, its Tax Provisions stood at -$1.0 million for Q4 2024, which was down 15139.66% from $242000.0 recorded in Q1 2024.
  • In the past 5 years, Amylyx Pharmaceuticals' Tax Provisions registered a high of $2.0 million during Q4 2023, and its lowest value of -$1.0 million during Q4 2024.
  • Moreover, its 3-year median value for Tax Provisions was $221000.0 (2022), whereas its average is $527500.0.
  • Examining YoY changes over the last 5 years, Amylyx Pharmaceuticals' Tax Provisions showed a top increase of 131440.0% in 2023 and a maximum decrease of 21643.84% in 2023.
  • Amylyx Pharmaceuticals' Tax Provisions (Quarter) stood at $574000.0 in 2022, then soared by 243.03% to $2.0 million in 2023, then plummeted by 151.4% to -$1.0 million in 2024.
  • Its Tax Provisions stands at -$1.0 million for Q4 2024, versus $242000.0 for Q1 2024 and $2.0 million for Q4 2023.